Aquapharm and AMRI enter into a novel marine chemistry collaboration

08-Jul-2010 - United Kingdom

Aquapharm Biodiscovery announced it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.

Under the terms of this agreement, drawing on its substantial experience and expertise from previous screening campaigns with its terrestrial natural products library, AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target and will isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration.

The collaboration represents a major step-forward for Aquapharm in realising the potential of its unique marine assets and expertise in the Pharmaceutical sector. This builds on its established deals with Croda to develop novel bio-active ingredients for the Personal Care industry and Dr Reddy’s to develop bio-catalysts, thus maximising the exploitation of the marine collection in producing a broad and diverse chemical library.

Initial results from this research agreement are expected during 2011. AMRI has broad screening capabilities and moreover particular expertise in seeking antibacterial natural products, having successfully completed its own internal screen of its collections yielding multiple lead compounds effective against MRSA and E.Coli organisms.

Other news from the department business & finance

Most read news

More news from our other portals